박셀바이오 / 2021.06.30 [정정] 사업보고서
1. 요약재무정보
주식회사 박셀바이오
(단위 : 원)
구분
2020년
(제11기)
2019년
(제10기)
2018년
(제9기)
회계처리기준
K-IFRS
K-IFRS
K-IFRS
감사인(감사의견)
신한회계법인 (적정)
한영회계법인 (적정)
한영회계법인 (적정)
[유동자산]
19,186,220,000,000
8,317,291,000,000
11,545,943,000,000
현금및현금성자산
9,902,560,000,000
4,074,423,000,000
4,446,466,000,000
[비유동자산]
16,311,292,000,000
1,718,444,000,000
712,242,000,000
자산총계
35,497,513,000,000
10,035,735,000,000
12,258,184,000,000
[유동부채]
594,186,000,000
425,728,000,000
15,128,687,000,000
[비유동부채]
235,910,000,000
538,737,000,000
9,324,575,000,000
부채총계
830,096,000,000
964,465,000,000
24,453,262,000,000
[자본금]
3,761,500,000,000
3,254,143,000,000
1,772,500,000,000
[자본잉여금]
51,913,354,000,000
23,054,474,000,000
1,918,514,000,000
[결손금]
(21,287,576,000,000)
(17,358,510,000,000)
(15,886,092,000,000)
자본총계
34,667,417,000,000
9,071,270,000,000
(12,195,078,000,000)
구분
사업연도(기간)
2020.01.01~ 2020.12.31
2019.01.01~ 2019.12.31
2018.01.01~ 2018.12.31
매출
-
-
영업이익(손실)
(4,254,895,000,000)
(4,010,647,000,000)
(2,422,429,000,000)
법인세비용차감전순이익(손실)
(3,984,015,000,000)
(1,253,758,000,000)
(6,447,695,000,000)
당기순이익(손실)
(3,984,015,000,000)
(1,253,758,000,000)
(6,447,695,000,000)
총포괄이익(손실)
(3,929,065,000,000)
(1,472,419,000,000)
(6,496,542,000,000)
기본주당손익(손실) (단위: 원)
(585)
(286)
(1,819)